Crossmark

The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses

Crossref DOI link: https://doi.org/10.1007/s00018-021-04085-1

Published Online: 2022-01-10

Published Print: 2022-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schreiber, André

Viemann, Dorothee

Schöning, Jennifer

Schloer, Sebastian

Mecate Zambrano, Angeles

Brunotte, Linda

Faist, Aileen

Schöfbänker, Michael

Hrincius, Eike

Hoffmann, Helen

Hoffmann, Markus

Pöhlmann, Stefan

Rescher, Ursula

Planz, Oliver

Ludwig, Stephan https://orcid.org/0000-0002-0362-8894
Funding

Funding for this research was provided by:

German Research Foundation (SFB1009 B02, B13, CRU342 P06, CRU342 P06, SFB1009 A06, VI 538-9-1, PO 716/11-1, PO 716/14-1)

Interdisciplinary Center for Medical Research (Bru2/015/19, Re/022/20)

Innovative Medical Research fund (SC121912)

Germany´s Excellence Strategy - EXC 2155 `RESIST` (39087428)

German Ministry of Education and Research (01KX2021, 01KI20218)

Westfälische Wilhelms-Universität Münster
License Information

Text and Data Mining valid from 2022-01-01

Version of Record valid from 2022-01-10
More Information

Article History

Received: 27 September 2021

Revised: 7 December 2021

Accepted: 8 December 2021

First Online: 10 January 2022

Declarations

:

: S.L. and O.P. are cofounders of Atriva Therapeutics GmbH, Tuebingen, Germany. O.P. serves as a CSO of the company; S.L. is member of the advisory board. H.H. is an employee of Atriva Therapeutics GmbH.

: The human primary nasal AEC studies were approved by the Institutional Review Board of the Hannover Medical School (no. 8014_BO_S_2018). Written informed consent was obtained from all participating individuals.

: Not applicable.

: Not applicable.

Document is current

Any future updates will be listed below